Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top 10 Correlated ETFs
EGTX.ST
Top 10 Correlated Stocks
EGTX.ST
Financial details
Company Rating
Buy
Market Cap
839.04M
Income
-104.99M
Revenue
42.13M
Book val./share
2.77
Cash/share
0.59
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
19 Aug 2022
P/E
-6.63
Forward P/E
-
PEG
0.85
P/S
16.52
P/B
1.4
P/C
6.54
P/FCF
-5.07
Quick Ratio
3.24
Current Ratio
3.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.58
EPS next Y
-
EPS next Q
-
EPS this Y
-63.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-10.89%
Revenue last 5Y
23%
Revenue Q/Q
14.36%
EPS Q/Q
83.51%
-
-
-
-
SMA20
-8.37%
SMA50
-3.04%
SMA100
-27.19%
Inst Own
-
Inst Trans
-
ROA
-20%
ROE
-19%
ROC
-0.2%
Gross Margin
-131%
Oper. Margin
-243%
Profit Margin
-249%
Payout
-
Shs Outstand
214.59M
Shs Float
84.66M
-
-
-
-
Target Price
-
52W Range
3.005-7.99
52W High
-44.86%
52W Low
+28.67%
RSI
48.01
Rel Volume
0.68
Avg Volume
160.37K
Volume
109.1K
Perf Week
-1.28%
Perf Month
-9.6%
Perf Quarter
-28.52%
Perf Half Y
-32.75%
-
-
-
-
Beta
1.20719
-
-
Volatility
0.07%, 0.29%
Prev Close
1.58%
Price
3.86
Change
5.32%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.28 | 0.57 | 1.58 | 0.6 | 0.36 | |
| Net income per share | -1.78 | -1.72 | -1.17 | -2.66 | -1 | |
| Operating cash flow per share | -1.75 | -1.63 | -1.2 | -2 | -1.24 | |
| Free cash flow per share | -1.75 | -1.63 | -1.2 | -2 | -1.24 | |
| Cash per share | 6.27 | 4.65 | 4.87 | 4.27 | 1.37 | |
| Book value per share | 6.15 | 4.44 | 4.67 | 9.34 | 5.02 | |
| Tangible book value per share | 6.15 | 4.44 | 4.67 | 0.6 | 1.1 | |
| Share holders equity per share | 6.15 | 4.44 | 4.67 | 9.34 | 5.02 | |
| Interest debt per share | 0 | 0 | 0 | 0.07 | 0.04 | |
| Market cap | 896.34M | 787.7M | 712.49M | 487.24M | 616.81M | |
| Enterprise value | 586.81M | 557.82M | 457.51M | 204.06M | 476.99M | |
| P/E ratio | -10.19 | -9.27 | -11.6 | -2.72 | -5.9 | |
| Price to sales ratio | 65.98 | 27.92 | 8.63 | 11.98 | 16.13 | |
| POCF ratio | -10.36 | -9.81 | -11.37 | -3.62 | -4.74 | |
| PFCF ratio | -10.36 | -9.81 | -11.37 | -3.62 | -4.73 | |
| P/B Ratio | 2.95 | 3.59 | 2.91 | 0.77 | 1.17 | |
| PTB ratio | 2.95 | 3.59 | 2.91 | 0.77 | 1.17 | |
| EV to sales | 43.2 | 19.77 | 5.54 | 5.02 | 12.47 | |
| Enterprise value over EBITDA | -6.67 | -6.56 | -7.48 | -1.14 | -4.68 | |
| EV to operating cash flow | -6.78 | -6.95 | -7.3 | -1.52 | -3.67 | |
| EV to free cash flow | -6.78 | -6.95 | -7.3 | -1.52 | -3.66 | |
| Earnings yield | -0.1 | -0.11 | -0.09 | -0.37 | -0.17 | |
| Free cash flow yield | -0.1 | -0.1 | -0.09 | -0.28 | -0.21 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
| Debt to assets | 0.04 | 0.09 | 0.09 | 0.3 | 0.07 | |
| Net debt to EBITDA | 3.52 | 2.7 | 4.17 | 1.58 | 1.37 | |
| Current ratio | 27.05 | 10.67 | 10.76 | 4.28 | 3.9 | |
| Interest coverage | 0 | -87K | -9.52K | -178.15K | -562.13 | |
| Income quality | 0.98 | 0.94 | 1.02 | 0.75 | 1.24 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.15 | 0.4 | 0.16 | 0.27 | 0.38 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.66 | 0.72 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -0.06 | -0.07 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.03 | |
| Graham number | 15.7 | 13.12 | 11.1 | 23.64 | 10.61 | |
| ROIC | -0.29 | -0.4 | -0.27 | -0.22 | -0.2 | |
| Return on tangible assets | -0.28 | -0.35 | -0.23 | -0.59 | -0.66 | |
| Graham Net | 6.03 | 4.2 | 4.39 | 0.37 | 0.97 | |
| Working capital | 303.71M | 219.36M | 244.87M | 229.73M | 113.73M | |
| Tangible asset value | 0 | 0 | 0 | 40.27M | 115.73M | |
| Net current asset value | 303.71M | 219.36M | 244.75M | 35.53M | 110.67M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 10.79M | 15.39M | 13.41M | 15.61M | 10.1M | |
| Average inventory | 0 | 0 | 0 | 3.14M | 1.92M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 29.38 | 66.05 | 36.44 | 30.77 | 17.38 | |
| Days of inventory on hand | 0 | 0 | 0 | 6.19 | 2.62 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 12.42 | 5.53 | 10.02 | 11.86 | 21 | |
| Inventory turnover | 0 | 0 | 0 | 59.01 | 139.09 | |
| ROE | -0.29 | -0.39 | -0.25 | -0.28 | -0.2 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-03-31 for Q1
| Metric | History | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.09 | 0.02 | 0.15 | 0.04 | 0.04 | |
| Net income per share | -1.39 | -0.12 | -0.21 | -0.14 | -0.16 | |
| Operating cash flow per share | -0.72 | -0.21 | -0.23 | -0.19 | -0.18 | |
| Free cash flow per share | -0.72 | -0.21 | -0.23 | -0.19 | -0.18 | |
| Cash per share | 5.3 | 1.51 | 1.26 | 1.05 | 0.59 | |
| Book value per share | 11.59 | 3.7 | 3.49 | 3.36 | 2.77 | |
| Tangible book value per share | 0.74 | 0.13 | -0.08 | -0.21 | 0.49 | |
| Share holders equity per share | 11.59 | 3.7 | 3.49 | 3.36 | 2.77 | |
| Interest debt per share | 0.09 | 0.03 | 0.03 | 0.02 | 0 | |
| Market cap | 405.8M | 995.36M | 926.03M | 997.01M | 899.53M | |
| Enterprise value | 122.62M | 750.11M | 723.51M | 823.86M | 792.75M | |
| P/E ratio | -1.35 | -12.88 | -6.74 | -11.06 | -7.8 | |
| Price to sales ratio | 82.99 | 262.84 | 36.99 | 160.55 | 126.66 | |
| POCF ratio | -10.4 | -28.43 | -24.26 | -32.21 | -27.12 | |
| PFCF ratio | -10.39 | -28.38 | -24.23 | -32.21 | -27.12 | |
| P/B Ratio | 0.64 | 1.63 | 1.61 | 1.8 | 1.8 | |
| PTB ratio | 0.64 | 1.63 | 1.61 | 1.8 | 1.8 | |
| EV to sales | 25.07 | 198.07 | 28.9 | 132.67 | 111.62 | |
| Enterprise value over EBITDA | -1.63 | -39.76 | -21.81 | -45.33 | -28.21 | |
| EV to operating cash flow | -3.14 | -21.43 | -18.95 | -26.62 | -23.9 | |
| EV to free cash flow | -3.14 | -21.39 | -18.93 | -26.62 | -23.9 | |
| Earnings yield | -0.19 | -0.02 | -0.04 | -0.02 | -0.03 | |
| Free cash flow yield | -0.1 | -0.04 | -0.04 | -0.03 | -0.04 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Debt to assets | 0.3 | 0.28 | 0.31 | 0.29 | 0.07 | |
| Net debt to EBITDA | 3.77 | 13 | 6.1 | 9.53 | 3.8 | |
| Current ratio | 4.28 | 5.2 | 3.54 | 5.27 | 3.61 | |
| Interest coverage | 9.14K | -1.15K | -72.19 | -5.31 | -735.63 | |
| Income quality | 0.52 | 1.81 | 1.11 | 1.37 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.92 | 1.19 | 0.16 | 0.37 | 0.76 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.66 | 0.69 | 0.71 | 0.76 | 0.77 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | -0.02 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -0.16 | -0.07 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 19.03 | 3.12 | 4.04 | 3.21 | 3.16 | |
| ROIC | -0.09 | -0.02 | -0.04 | -0.03 | -0.06 | |
| Return on tangible assets | -0.25 | -0.07 | -0.14 | -0.12 | -0.23 | |
| Graham Net | 0.46 | 0.06 | -0.28 | -0.3 | 0.4 | |
| Working capital | 229.73M | 207.61M | 170.53M | 148.63M | 86.17M | |
| Tangible asset value | 40.27M | 21.42M | -12.41M | -34.13M | 88.03M | |
| Net current asset value | 35.53M | 16.78M | -17.43M | -39.54M | 83.37M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 12.2M | 6.26M | 21.77M | 8.8M | 7.24M | |
| Average inventory | 2.05M | 1.52M | 1.3M | 964K | 702K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 20.74 | 27.8 | 65.4 | 50.53 | 23.63 | |
| Days of inventory on hand | 4.17 | 15.51 | 3.08 | 5.54 | 1.83 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 4.34 | 3.24 | 1.38 | 1.78 | 3.81 | |
| Inventory turnover | 21.59 | 5.8 | 29.22 | 16.25 | 49.27 | |
| ROE | -0.12 | -0.03 | -0.06 | -0.04 | -0.06 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Company Profile
- Volume Average 160.37K
- Market Capitalization 839.04M
- Employee 13
- Headquarters Stockholm,SE
- IPO Date 2011-04-07
-
Website
https://www.egetis.com 
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
